Susquehanna International Group
APLS

Susquehanna International Group’s Apellis Pharmaceuticals APLS Stock Holding History

Susquehanna International Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.58M Buy
163,600
+52,800
+48% +$1.14M ﹤0.01% 3777
2025
Q4 		$2.78M Buy
110,800
+35,100
+46% +$824K ﹤0.01% 5005
2025
Q3 		$1.71M Sell
75,700
-90,200
-54% -$2.1M ﹤0.01% 6122
2025
Q2 		$2.87M Sell
165,900
-3,700
-2% -$68.5K ﹤0.01% 5043
2025
Q1 		$3.71M Buy
169,600
+17,000
+11% +$470K ﹤0.01% 4228
2024
Q4 		$4.87M Sell
152,600
-60,200
-28% -$1.81M ﹤0.01% 3636
2024
Q3 		$6.14M Sell
212,800
-62,100
-23% -$2.3M ﹤0.01% 3271
2024
Q2 		$10.5M Sell
274,900
-56,200
-17% -$2.55M ﹤0.01% 2426
2024
Q1 		$19.5M Sell
331,100
-56,100
-14% -$3.58M ﹤0.01% 1805
2023
Q4 		$23.2M Sell
387,200
-8,500
-2% -$431K ﹤0.01% 1651
2023
Q3 		$15.1M Buy
395,700
+166,900
+73% +$7.33M ﹤0.01% 2070
2023
Q2 		$20.8M Sell
228,800
-107,600
-32% -$9.28M ﹤0.01% 1681
2023
Q1 		$22.2M Buy
336,400
+117,400
+54% +$6.77M ﹤0.01% 1607
2022
Q4 		$11.3M Buy
219,000
+66,500
+44% +$3.53M ﹤0.01% 2119
2022
Q3 		$10.4M Buy
152,500
+81,000
+113% +$4.79M ﹤0.01% 2099
2022
Q2 		$3.23M Sell
71,500
-65,400
-48% -$2.98M ﹤0.01% 3927
2022
Q1 		$6.96M Buy
136,900
+83,200
+155% +$3.67M ﹤0.01% 3096
2021
Q4 		$2.54M Sell
53,700
-697,400
-93% -$27.5M ﹤0.01% 4967
2021
Q3 		$24.8M Buy
751,100
+257,100
+52% +$14.4M ﹤0.01% 1757
2021
Q2 		$31.2M Buy
494,000
+403,100
+443% +$20.8M ﹤0.01% 1567
2021
Q1 		$3.9M Buy
90,900
+32,500
+56% +$1.54M ﹤0.01% 4401
2020
Q4 		$3.34M Buy
58,400
+17,400
+42% +$736K ﹤0.01% 4129
2020
Q3 		$1.24M Sell
41,000
-66,100
-62% -$1.97M ﹤0.01% 5611
2020
Q2 		$3.5M Sell
107,100
-33,300
-24% -$1.07M ﹤0.01% 3541
2020
Q1 		$3.76M Buy
140,400
+15,100
+12% +$536K ﹤0.01% 2950
2019
Q4 		$3.84M Buy
125,300
+108,100
+628% +$2.99M ﹤0.01% 3348
2019
Q3 		$414K Buy
+17,200
New +$473K ﹤0.01% 7682

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group's APLS Position: Q1 2026 in Review

Susquehanna International Group reduced its Apellis Pharmaceuticals (APLS) stake by 36% in Q1 2026, selling an estimated $4.18M and leaving 340,086 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.

Susquehanna International Group first reported a position in APLS in Q2 2019 and has held it in 28 quarters since. The position peaked at $28.8M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Susquehanna International Group held 340,086 shares of Apellis Pharmaceuticals worth $13.7M as of Q1 2026.
  • Susquehanna International Group sold 193,823 Apellis Pharmaceuticals shares in Q1 2026, an estimated $4.18M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2675 holding.
  • Susquehanna International Group first reported a position in Apellis Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Susquehanna International Group's Apellis Pharmaceuticals position peaked at $28.8M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.